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Abstract: Leishmaniasis is a disease caused by the protozoan parasites 
Leishmania, infecting numerous mammal species. Canine leishmaniasis 
is potentially zoonotic and causes severe fatal disease in dogs. The 
discovery of new natural products extracted from medicinal plants or 
compounds derived from them, such as quercetin, hesperidin, vitamin c, 
horse chestnut extract and selenium could represent a valuable source of 
new medicinal agents for treating leishmaniasis in dogs. 
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Introduction 
Leishmaniosisis a disease caused by more than 20 
protozoan parasites of the genus Leishmania. These 
parasites are transmitted by the bite of phlebotomine 
sand flies and can infect numerous mammalian species, 
including humans. Leishmaniasis has a distribution 
ranging through America and Africa and extending into 
temperate regions of Latin America, Europe and Asia. 
The World Health Organization has identified human 
leishmaniasis as one of the most neglected tropical 
diseases. Visceral leishmaniasis is widespread in more 
than 80 countries and it is the most serious form, fatal in 
more than 95% of cases within 2 years after the onset of 
the disease. Some 90% of all new cases are reported 
from six countries: Brazil, Ethiopia, India, Somalia, 
South Sudan and Sudan 
(www.who.int/leishmaniasis/en/).  
In contrast, pets are infected with different 
Leishmania species. L. infantum is the most widespread 
in domestic animals and dogs represent the main 
domestic zoonotic reservoir for visceral leishmaniasis. In 
addition, canine leishmaniasis (CanL) causes severe and 
often fatal disease in this animal species. Clinical 
diagnosis in cats of Feline Leishmaniasis syndrome 
(FeL) in endemic areas is not common. This may be due 
to their grooming habits that seem to minimize the risk 
for arthropod infection compared to dogs or the 
subclinical infection that occurs in most infected cats, or 
finally, because veterinary practitioners do not usually 
consider this disease in the list of differential diagnosis 
of their feline patients (Otranto et al., 2017). Horses and 
domestic equines suffer occasionally from single or 
multiple cutaneous lesions but probably they represent 
an incidental host of the disease (Gramiccia, 2011). 
Clinical Signs in Canine Leishmaniasis 
CanL is a severe disease induced by panosomatid 
species of the genus Leishmania. It is estimated that 
almost thirty species from the genus Leishmania can be 
responsible for this disease. L. infantum has been 
identified as a major, potentially fatal, zoonotic infection 
in regions of Europe, Africa, Asia and America 
(Gramiccia and Gradoni, 2005), although other species 
such as L. chagasi, L. mexicana, L. braziliensis, L. 
donovani or L. amazonensis are also potential etiologic 
agents (Lainson and Shaw, 2005; Alvar et al., 2004). Due to 
their close association with people, dogs are considered the 
main reservoir of human infection and phlebotomine sand 
flies are the biological vectors of this protozoal disease 
(Reguera et al., 2016; Baneth et al., 2008). 
CanL results in several serious clinical signs in 
infected dogs. The parasite target cell is the macrophage, 
which becomes the site of parasite replication inhibiting 
its antimicrobial activities (Gramiccia, 2011). The 
majority of clinical dogs show poor body condition, 
generalized muscular atrophy, lymphadenomegaly, 
excessive skin scaling, decreased appetite and lethargy 
(Ciaramella et al., 1997; Koutinas et al., 1999; 2001; 
Baneth et al., 2008). Progressive muscle atrophy is 
associated with chronic polymyositis characterized by 
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the presence of mononuclear infiltrates with Leishmania 
amastigotes, neutrophilic vasculitis and IgG immune 
complexes in muscle tissues in conjunction with serum 
anti-myofiber antibodies (Vamvakidis et al., 2000). The 
dermal symptoms include exfoliative, ulcerative, nodular 
and pustular dermatitis, alopecia and onychogryphosis; 
in addition, dogs may present with epistaxis, diarrhea 
and splenomegaly (Noli and Auxilia, 2014; Baneth et al., 
2008). Other symptoms are the marked enlargement of 
lymph nodes caused by the increased number and size of 
lymphoid follicles and the marked hypertrophy and 
hyperplasia of medullary macrophages in the cords and 
sinuses (Lima et al., 2004). The splenomegaly is 
associated with increased monocyte and macrophage 
cellularity and changes in the microvasculature structure 
with abundant pulp venules and veins and increased 
reticular fibers (Alexandre-Pires et al., 2006). Renal 
disease can be the result of tubulointerstitial nephritis, 
glomerulonephritis and amyloidosis with a progression 
from asymptomatic proteinuria to nephrotic syndrome or 
chronic renal disease with azotemia (Koutinas et al., 
1999). Joint and bone lesions are frequently present with 
periosteal and intra-medullary proliferative lesions and 
cortical and medullary osteolysis (Nieto et al., 1992; 
Agut, et al., 2003; Blavier et al., 2001). Ocular lesions 
are present in 16 to 80.5% of dogs and consist of anterior 
uveitis, conjunctivitis, dry keratoconjunctivitis and 
blepharitis (Ciaramella et al., 1997; Koutinas et al., 1999; 
2001; Naranjo et al., 2005; Peña et al., 2000). Epistaxis, 
hematuria and hemorrhagic diarrhoea are associated with 
tissue ulceration and alterations in primary and 
secondary hemostasis. Hemostatic disorders include 
platelet aggregation abnormalities leading to platelet 
dysfunction, thrombocytopenia and decreased 
coagulation factor activities (Ciaramella et al., 2005). 
Profuse epistaxis can be the only presenting sign of 
disease and can cause death because of uncontrollable 
blood loss secondary to pyogranulomatous or 
lymphoplasmacytic rhinitis, thrombocytopathy and 
hyperglobulinemia (Juttner et al., 2001). Anemia is 
present in the majority of symptomatic dogs because of 
chronic renal disease or decreased erythropoiesis caused 
by chronic disease and can be aggravated by blood loss 
or immune mediated destruction of red blood cells 
(Ciaramella et al., 1997; Koutinas et al., 1999; 2001). 
Current Therapies for the Treatment of CanL 
Several drugs used for the treatment of CanL are able 
to improve clinical signs temporarily or cure dogs 
clinically, but none of these treatments reliably 
eliminates the infection (Miró et al., 2008). Nowadays, 
chemotherapy is the most efficient treatment for sick 
dogs and shows benefits in terms of reduction of 
prevalence and incidence of the disease, as well as in the 
control of pathogen’s life cycle (Miró et al., 2011). 
Current chemotherapy is based on monotherapy or 
combination therapy of leishmanicidal and 
leishmaniostatic drugs. Disadvantages of these first-
choice drugs are that they require parenteral delivery 
by veterinarian practitioners and the treatment is long 
and unpleasant for dogs and owners. Undesirable toxic 
side effects, particularly initiation or exacerbation of 
renal disease are not uncommon (Miró et al., 2008; 
Valladares et al., 1998). Furthermore, relapses are 
extremely frequent (up to 74%) in the first year post-
treatment (Slappendel and Teske, 1997). Finally, 
development of drug-resistant strains of the parasite can 
be a consequence of drug misuse or can be due to host 
factors (modifications of pharmacokinetic parameters or 
an alteration in the immunological response to the 
parasite) and parasite factors (structural modifications of 
target proteins or mechanisms to evade the host 
immunological system) (Rhalem et al., 1999). 
Prevention (or Preventive Measures) 
Vaccines are an alternative to chemotherapy drugs. 
These stimulate the immune response with the aim of 
preventing infection and disease progression and 
blocking the parasite’s life cycle. Many studies in animal 
models have shown that after inoculation of infective 
metacyclic promastigotes by the sand fly, skin dendritic 
cells are responsible for phagocytosis and antigen 
presentation to T cells. Afterwards, they migrate to 
the nearest lymph node to present the antigens to 
immature T cells and cause proliferation of CD4+ and 
CD8+ T cells. At this moment, a classical 
dichotomous cell-mediated response is triggered, this 
can be protective (Th1) or not protective (Th2), thus 
resulting in resistance or susceptibility to Leishmania 
infection. Vaccines can adequately boost the 
immunological system against a potential infection, 
thus avoiding the toxicity of chemotherapy and the 
emergence of resistant strains. However, prevention of 
CanL also involves reducing exposure to vectors 
using formulations with repellent/insecticide activity 
such us a large number of insecticide containing 
deltamethrin or combination of permethrin and 
neonicotinoid insecticide (Reguera et al., 2016). 
New Alternatives from Natural Products 
Extracts from medicinal plants or compounds derived 
from them are a valuable source of new medicinal agents 
for the treatment of leishmaniasis. There is a large 
range of families and species of plants with a potentially 
active leishmanicidal effect. The leishmanicidal effect 
may reside in phytochemical components such as 
flavonoids and, specifically, quercetin, which is a 
strong candidate in the combination therapy for the 
treatment of (Marìn et al., 2009) 
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Quercetin 
Quercetin is a naturally occurring flavonoid 
isolated from Fagopyrum esculentum (Polygonaceae) 
(Polonio and Efferth, 2008). This compound shows 
potent anti-Leishmania activity in vitro on the 
amastigote stage of L. donovani and L. amazonensis. 
Most of the beneficial health effects of this flavonoid are 
attributed to its antioxidant and chelating activities, via 
scavenging of reactive oxygen species/metal chelation 
and stimulation/inhibition of enzyme activities/signal 
transduction pathways. Concerning its mechanism of 
action, quercetin is able to induce topoisomerase II-
mediated kinetoplastid DNA minicircle cleavage in L. 
donovani promastigotes and intracellular amastigotes. 
The treatment of promastigotes with quercetin leads to 
cell cycle arrest in the G0/G1 phase followed by 
apoptotic cell death. Quercetin is a specific inhibitor of 
topoisomerase I, which is an unusual bi-subunit 
topoisomerase in Leishmania. Additionally, this 
compound can chelate iron, which translates into a 
decreased availability of the iron dependent ribonucleotide 
reductase, a rate limiting enzyme for DNA synthesis 
(Polonio and Efferth, 2008; Sen and Chatterjee, 2011; 
Sen et al., 2005; Fiorania et al., 2010; Sen et al.,2008; 
Da Silva et al., 2012). 
In recent years, quercetin is becoming increasingly 
popular as a dietary supplement for pets. This 
compound has been suggested to have various 
beneficial effects like preventing cancer, suppressing 
inflammation or decreasing fat absorption and age-
related diseases that are associated with increased 
oxidative stress (Reinboth et al., (2010). 
In a study by Reinboth et al. (2010), a single 
administration of quercetin in dogs at the dose of 150 
mg/subject (about 10 mg kg
−1
) showed a maximum 
plasma concentration (Cmax) of 234 nmol L
−1
 (equivalent 
to 0.77 µg mL
−1
) and a very low bioavailability (4%). 
These results are in agreement with different studies 
present in literature on other animal species. Indeed, in 
rats and pigs the absolute bioavailability of quercetin 
was only 5 and 1%, respectively (Wessmann et al., 2000; 
Chen et al., 2005). Due to the low bioavailability of 
quercetin after oral administration in different animal 
species, a study performed by Medalpharma sas industry 
in 2012 (internal data) investigated the 
pharmacokinetics of quercetin in dogs after a single 
administration at 150 mg kg
−1
 b.w. No visible side 
effects were observed immediately after the single 
administration or over the subsequent seven days. The 
Cmax of quercetin after a single dose (150 mg kg
−1
 b.w.) 
was 11 µg mL
−1
. Findings of this study suggest that, if 
compared with a previous study in dogs (Reinboth et al., 
2010; dose: 10 mg kg
−1
; Cmax: 0.77 µg mL
−1
), quercetin 
is expected to have linear first-order kinetics in dogs for 
doses ranging from 10 to 150 mg kg
−1
. Unfortunately, no 
pharmacokinetic/pharmacodynamic studies are 
available concerning a clinical dose of quercetin for the 
treatment of CanL.  
The IC 50 (50% inhibition concentration of cell 
growth) value against L. donovani and L. amazonensis 
intracellular amastigotes is 1.0 µg mL
−1
. If this value is 
multiplied for 24 h, a value of AUC0-24h of 24 µg*h mL
−1
 
is calculated. This parameter represents the theoretical 
value to maintain the plasma concentration of quercetin 
above the IC 50 for 24 h. Bearing in mind the dose 
proportional feature of quercetin and tha ta dose of 150 
mg kg
−1
 showed a value of AUC0-24h: 129 µg*h mL
−1
 
(Medalpharma sas, internal data, 2012), it can be 
calculated that a dose of 28 mg kg
−1
 produces an AUC0-
24h 24 µg*h mL
−1
 maintaining the plasma concentration 
of quercetin above the IC 50 for one day. 
Hesperidin 
Hesperidin is an abundant flavonoid produced by 
citrus cultivations and it is the major product of oranges 
and lemons. It is usually administered in association with 
vitamin C to increase the efficacy of the compound and 
it has been shown to possess an excellent safety profile 
(Garg et al., 2001). 
Due to its broad spectrum of activities, hesperidin is 
effectively used as a supplemental agent in numerous 
treatment programmes. One of the main effect of 
hesperidin is on the vascular system. Hesperidin 
supplementation has been used in patients suffering with 
blood vessel disorders including those involving abnormal 
permeability and fragility of capillary walls (resulting in 
oedema, bleeding and hypertension) (Garg et al., 2001). 
The role of hesperidin in increasing capillary resistance 
has been attributed to its inhibitory effect on the action 
of hyaluronidase enzyme that accentuate capillary 
permeability and fragility. In a study on human patients, 
hesperidin inhibited epinephrine and ADP-induced 
platelet aggregation at a concentration of 0.08 mg mL
−1
. 
In another study on horses, hesperidin was found to 
effectively reduce aggregation of erythrocytes. This 
decrease in erythrocyte aggregation may explain the 
beneficial effects of hesperidin on the abnormal 
permeability and fragility of capillary walls. Hesperidin 
has been shown to possess significant anti-inflammatory 
and analgesic effects. This effect could be attributed to 
the inhibition of the release of histamine from basophils 
by hesperidin or its metabolic products. This compound 
showed anti-infective and anti-replicative activities in vitro 
against several plant and animal microbes (Garg et al., 
2001). Finally, hesperidin has been reported to possess 
antioxidant and immuno-suppressant properties. Indeed, 
after intragastric administration of hesperidin at the dose of 
50 mg kg
−1
, this compound suppressed bacterial alpha-
amylase antibody production in mice and significantly 
increased the development of immunological memory 
in the cellular immune response (Kim and Cho, 1991). 
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Concerning the pharmacokinetics of hesperidin, in a 
study by Ameer et al. (1996), the authors evaluated the 
oral absorption of hesperidin in healthy young human 
volunteers at the dose of 500 mg/subject (about 7 mg 
kg
−1
) showing a low bioavailability (about 25%). 
Furthermore, a study performed by Medalpharma sas 
industry in 2012 (internal data), reported the 
pharmacokinetics of hesperidin in dogs after a single 
administration at the dose of 150 mg kg
−1
 b.w. No 
visible side effects were observed immediately after the 
single administration or over the subsequent seven 
days. The Cmax of hesperidin after a single dose (150 
mg kg
−1
 b.w.) was 7 µg mL
−1
.  
No pharmacokinetic/pharmacodynamic studies are 
available concerning the clinical dose of hesperidin 
for the treatment of CanL. From the studies reported 
above it can be summarized that doses from 7 to 50 
mg kg
−1
 might produce suitable plasma concentrations 
of hesperidin to effectively treat CanL, while higher 
doses up to 150 mg kg
−1
 were shown not to evoke 
appreciable adverse effects. 
Vitamin C 
Leishmaniosis is accompanied by severe anemia and 
shortened lifespan of erythrocytes. Several lines of 
evidence suggest an important role of enhanced lipid 
peroxidation in the pathogenesis of hemolytic anemia. In 
healthy animals the cells invest much of their 
metabolic activity in the reductive processes that 
combat the threat of oxidation. Glutathione (GSH), 
with glutathione redox cycle in the cell, is involved in 
several defence processes against oxidative damage. 
Obviously, a deficiency of these antioxidants 
increases cells’ susceptibility to oxidative damage. 
Vitamin C (ascorbic acid) is a powerful antioxidant 
that reacts rapidly with a variety of oxidants, including 
the rather poorly reactive superoxide anion radical 
(Bildik et al., 2004). It is transported into erythrocytes 
as dehydroascorbic acid, which is then reduced to 
ascorbate via a GSH-dependent reaction.  
A study by Field and Rekers, (1949) showed that 
supplementary treatment with vitamin C in dogs (100 
mg orally three times daily for 1 week) might 
potentiate the anti-hemorrhagic action of the 
flavanones quercetin. Furthermore, vitamin C is usually 
administered in association with another flavonoid 
hesperidin to increase the efficacy of the final compound, 
this combination has been shown to be extremely safe and 
without side effects (Garg et al., 2001). 
In light of the features mentioned above, vitamin C 
might be a potential new natural compound for the 
treatment some clinical signs of CanL. 
Horse Chestnut Extract  
The active compound β-aescin is the main saponin 
isolated from the seeds of the horse-chestnut Aesculus 
hippocastanumi (Sapindaceae). A study of Vermelho et al. 
(2014) showed a β-aesc in value equal to 1.04±0.23 ug 
mL
−1
 for L. infantum amastigotes and the Horse 
Chestnut Extract (HCE) contains 70% esc (Guillaume 
and Padioleau, 1994).  
Concerning its mechanism of action, HCE showed 
antiradical activity in both in vitro and in vivo studies 
inhibiting both enzymatic and non-enzymatic in vitro 
lipid peroxidation (in the concentration range 5×10
−6
 to 
5×10
−4
 g mL
−1
). Furthermore, additional studies have 
shown the veinotonic and lymphagogue properties of 
HCE at different dosages. Indeed, HCE dose 
dependently contracts the canine saphenous isolated vein 
for more than 5 h. In the perfused canine saphenous vein, 
HCE (25-50 mg in bolus) increases the venous pressure 
of the normal vein and the pathological vein by 
increasing the contractile response to noradrenaline. 
During the perfusion in the inverse direction of the blood 
flow, a clear contracting effect on the valves is also 
noted with HCE. In the anaesthetized dog, HCE in situ 
improves the femoral vein compliance and opposes the 
venous distension obtained during clamping in a 
carotido-femoral perfusion with constant flow. HCE 
significantly increases femoral venous pressure and flow, 
together with thoracic lymphatic flow, while respecting 
the arterial parameters (2.5 and 5 mg kg
−1
 intravenously). 
In regards to the vasculotropic action, HCE dose 
dependently diminishes the cutaneous capillary hyper 
permeability induced either by injections of 
inflammatory agents such as histamine and serotonin in 
the rat (100 to 400 mg kg
−1
 orally), or by an irritating 
agent like chloroform applied in the rabbit (50 to 300 mg 
kg
−1
 orally and 2.5 to 5 mg kg
−1
 intravenously). It 
significantly increases the vascular resistance in guinea 
pigs fed a scorbutigenic diet as measured by the petechia 
method (50 to 400 mg kg
−1
 orally). Regarding anti-
edema and anti-inflammatory activities, HCE decreases 
the formation of edema induced in the rat's hind paw, 
one of lymphatic origin, the other of inflammatory origin 
(200 to 400 mg kg
−1
 orally). In an experimental model of 
pleurisy in rats, HCE suppresses plasmatic extravasation 
and leucocytes emigration into the pleural cavity (200 to 
400 mg kg
−1
 oraly; 1 to 10 mg kg
−1
 intravenously). 
Finally, HCE decreases connective tissue formation in 
the subchronic, inflammatory granuloma model in the rat 
(400 mg kg
−1
 orally and 5-10 mg kg
−1
 subcutaneously) 
(Guillaume and Padioleau, 1994). 
Due to its broad mechanism of action, HCE might be 
considered a suitable supplementary therapy for the 
treatment of the main clinical signs of CanL. 
Selenium 
The final compound considered in the present work is 
selenium, a micronutrient element with broad functions 
in biological systems. Selenium ions (SeO2 is the 
chemical form of selenium) have antioxidant, cancer 
preventing and antiviral activities and also appear to 
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improve the immune response of hosts against various 
species of bacteria and viral antigens (Beheshti et al., 
2013; Rayman, 2012; Soflaei et al., 2014; Tapiero et al., 
2003). The IC50 of selenium for L. infantum is 50 µg 
mL
−1
 (Soflaei et al., 2014). 
Considering selenium activities and its IC50 value, 
this compound might be used against leishmaniasis with 
dose-dependent anti-leishmanial activities. 
Conclusion 
Leishmaniosisis a neglected, potentially lethal 
infectious disease for human and pets caused by 
parasites of the genus Leishmania that affects many 
developing countries. 
The treatment of leishmaniosis in pets is 
challenging and lengthy. Therapeutic problems 
include the toxicity of available drugs and increasing 
drug resistance. Leishmaniosis has received scarce 
attention from governments and the pharmaceutical 
industries until the past decade.  
The development of new parasite targets and synthetic 
drugs along with research on natural products such as 
quercetin, hesperidin, vitamin C, horse chestnut extract and 
selenium might represent a possible strategy for the 
discovery of new therapeutic agents against Leishmania. 
Although further studies are required to determine if these 
natural products can be used in the same formulation, these 
preliminary findings pave the road for their use as a 
supportive treatment for leishmaniosis in dogs. 
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